Use of granulocyte colony-stimulating factor in patients with severe sepsis or septic shock

American Journal of Health-System Pharmacy

Volumn 67, Issue 15, 2010, Pages 1238-1245

  Mohammad, Rima A ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Colony stimulating factor; Critical illness; Hematopoietic agents; Mortality; Sepsis; Septic shock; Toxicity

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTIANEMIC AGENT;

ACIDOSIS; ADULT RESPIRATORY DISTRESS SYNDROME; BONE PAIN; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART ARREST; HUMAN; HYPOTENSION; KIDNEY FAILURE; MORBIDITY; MORTALITY; MUSCULOSKELETAL PAIN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; STUDY DESIGN; TREATMENT OUTCOME; RANDOMIZED CONTROLLED TRIAL;

GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATINICS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SHOCK, SEPTIC;

EID: 78349291178     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090325     Document Type: Review

References (51)

1. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29:1303-10. (Pubitemid 32641789)
2. Dombrovskiy VY, Martin AA, Sunderram J et al. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007; 35:1244-50.
3. Stephens DP, Fisher DA, Currie BJ. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J. 2002; 32:143-8. (Pubitemid 36124669)
4. Weisbart RH, Golde DW. Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin North Am. 1989; 3:401-9. (Pubitemid 19210693)
5. Weiss M, Voglic S, Harms-Schirra B et al. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. Intensive Care Med. 2003; 29:904-14. (Pubitemid 36783160)
6. Nelson S. A question of balance. Am J Respir Crit Care Med. 1999; 159:1365-7.
7. Schafer H, Hubel K, Bohlen H et al. Perioperative treatment with filgrastim stimulates granulocyte function and reduces infectious complications after esophagectomy. Ann Hematol. 2000; 79:143-51. (Pubitemid 30195612)
8. Wenisch C, Werkgartner T, Sailer H et al. Effect of preoperative prophylaxis with filgrastim in cancer neck dissection. Eur J Clin Invest. 2000; 30:460-6. (Pubitemid 30251404)
9. Gough A, Clapperton M, Rolando N et al. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet. 1997; 350:855-9. (Pubitemid 27404347)
10. Neupogen (filgrastim) package insert. Thousand Oaks, CA: Amgen; 2007 Sep.
11. Neulasta (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen; 2010 Feb.
12. Mostyn G, Burgess AW. Hematopoietic growth factors: a review. Cancer Res. 1988; 48:5624-37.
13. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. N Engl J Med. 1992; 327:99-106.
14. Kubota N, Orita T, Hattori K. Structural characterization of natural and recombinant human granulocyte colony-stimulating factor. J Biochem. 1990; 107:486-92. (Pubitemid 20089122)
15. Curran MP, Goa KL. Pegfilgrastim. Drugs. 2002; 62:1207-13. (Pubitemid 34587575)
16. Kim IH, Park SK, Suh OK et al. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opin. 2003; 19:753-9. (Pubitemid 37466146)
17. Nissen C, Dalle Carbonare V, Moser Y. In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF. Drug Invest. 1994; 7:346-52. (Pubitemid 24179773)
18. Cheng AC, Stephens DP, Currie BJ. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev. 2007; 18(2):CD004400.
19. Leukine (sargramostim) package insert. Seattle, WA: Bayer HealthCare Pharmaceuticals; 2008 Apr.
20. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis. 1999; 179(suppl 2):S342-52.
21. Weiss M, Moldawer LL, Schneider EM. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood. 1999; 93:425-39. (Pubitemid 29035724)
22. O'Reilly M, Silver GM, Greenhalgh DG et al. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma. 1992; 33:679-82. (Pubitemid 23006754)
23. Hebert JC, O'Reilly M, Gamelli RL. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg. 1990; 125:1075-8. (Pubitemid 20249349)
24. Nelson S, Summer W, Bagby G et al. Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis. 1991; 164:901-6.
25. Mooney DP, Gamelli RL, O'Reilly M et al. Recombinant human colony-stimulating factor and Pseudomonas burn wound sepsis. Arch Surg. 1988; 123:1353-7. (Pubitemid 18262716)
26. Lundblad R, Wang MY, Kvalheim G et al. Granulocyte colony-stimulating factor improves myelopoiesis and host defense in fulminant intra-abdominal sepsis in rats. Shock. 1995; 4:68-73.
27. Haberstroh J, Breuer H, Lucke I et al. Effect of recombinant human granulocyte colony-stimulating factor on hemodynamic and cytokine response in a porcine model of Pseudomonas sepsis. Shock. 1995; 69:278-84.
28. Goya T, Torisu M, Doi F et al. Effects of granulocyte colony stimulating factor and monobactam antibiotics (aztreonam) on neutrophil functions in sepsis. Clin Immunol Immunopathol. 1993; 69:278-84.
29. Nelson S, Heyder AM, Stone J et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis. 2000; 182:970-3.
30. Nelson S, Belknap S, Carlson R et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis. 1998; 178:1075-80. (Pubitemid 28452201)
31. Ishikawa K, Tanaka H, Nakamori Y et al. Difference in the responses after administration of granulocyte colony-stimulating factor in septic patients with relative neutropenia. J Trauma. 2000; 48:814-25. (Pubitemid 30435947)
32. Knaus WA, Zimmerman JE, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13:818-28.
33. Goris RJ, te Boekhorst TP, Nuytinck JK et al. Multiple-organ failure: generalized autodestructive inflammation? Arch Surg. 1985; 120:1109-15. (Pubitemid 16229682)
34. Ishikawa K, Tanaka H, Matsuoka T et al. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) attenuates inflammatory responses in septic patients with neutropenia. J Trauma. 1998; 44:1047-55. (Pubitemid 28310968)
35. Tanaka H, Ishikawa K, Nishino M et al. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma. 1996; 40:718-26. (Pubitemid 26142752)
36. Kawakami M, Tsutsumi H, Kumakawa T et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood. 1990; 76:1962-4.
37. Stephens DP, Thomas JH, Dip G et al. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med. 2008; 36:448-54. (Pubitemid 351158618)
38. Dellinger RP, Levy MM, Carlet JM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36:296-327.
39. Cheng AC, Stephens DP, Anstey NM et al. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis. 2004; 38:32-7. (Pubitemid 38045870)
40. Wunderink RG, Leeper KV, Schein R et al. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest. 2001; 119:523-9. (Pubitemid 32163767)
41. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001; 29:2264-70. (Pubitemid 34038156)
42. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342:1301-8.
43. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001; 345:1368-77.
44. Brook AD, Ahrens TS, Schaiff R et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med. 1999; 27:2609-15. (Pubitemid 30027169)
45. Jimenez MF, Marshall JC. Source control in the management of sepsis. Intensive Care Med. 2001; 27(suppl 1):S49-62.
46. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002; 288:862-71.
47. Root RK, Lodato RF, Patrick W et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med. 2003; 31:367-73. (Pubitemid 36232927)
48. Schilero GJ, Oropello J, Benjamin E. Impairment in gas exchange after granulocyte colony stimulating factor (G-CSF) in a patient with adult respiratory distress syndrome. Chest. 1995; 107:276-8.
49. Takatsuka H, Takemoto Y, Mori A et al. Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor. Chest. 2002; 121:1716-20. (Pubitemid 34499699)
50. Wiedermann FJ, Mayr AJ, Hobisch-Hagen P et al. Association of endogenous G-CSF with anti-inflammatory mediators in patients with acute respiratory distress syndrome. J Interferon Cytokine Res. 2003; 23:729-36. (Pubitemid 38041444)
51. Wiedermann FJ, Mayr AJ, Kaneider NC et al. Alveolar granulocyte colony-stimulating factor and a-chemokines in relation to serum levels, pulmonary neutrophilia, and severity of lung injury in ARDS. Chest. 2004; 125:212-9. (Pubitemid 38114585)